AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour

Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer

(2021) Yu-Ling Lu et al.   Cancers

Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway

(2020) Xiangrui Meng et al.   Frontiers in Oncology

AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer

(2019) Francesca Collina et al.   Cancers

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2019) S Filetti et al.   ANNALS OF ONCOLOGY

TAM receptors, Phosphatidylserine, inflammation, and Cancer

(2019) Tal Burstyn-Cohen et al.   Cell Communication and Signaling

Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma

(2018) Hirokazu Sadahiro et al.   CANCER RESEARCH

Follow-up of differentiated thyroid cancer – what should (and what should not) be done

(2018) Livia Lamartina et al.   Nature Reviews Endocrinology

Evolving Understanding of the Epidemiology of Thyroid Cancer

(2018) Carolyn Dacey Seib et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

TAM receptor signaling in development

(2017) Tal Burstyn-Cohen   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

(2017) Masamichi Mori et al.   INVESTIGATIONAL NEW DRUGS

The autophagy marker LC3 strongly predicts immediate mortality after surgical resection for hepatocellular carcinoma

(2017) Chih-Wen Lin et al.   Oncotarget

Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL

(2017) Ghada Abboud-Jarrous et al.   Oncotarget

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin

(2017) Manoj Garg et al.   Scientific Reports

Role of protein S in castration-resistant prostate cancer-like cells

(2016) Peng Ning et al.   ENDOCRINE-RELATED CANCER

Clinicopathological features of recurrent papillary thyroid cancer

(2015) Jian Zhu et al.   Diagnostic Pathology

Cabozantinib in Thyroid Cancer

(2015) Poupak Fallahi et al.   Recent Patents on Anti-Cancer Drug Discovery

Current Thyroid Cancer Trends in the United States

(2014) Louise Davies et al.   JAMA Otolaryngology-Head & Neck Surgery

Axl is essential for VEGF-A-dependent activation of PI3K/Akt

(2012) Guo-Xiang Ruan et al.   EMBO JOURNAL

The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target

(2012) J D Paccez et al.   ONCOGENE

Epithelial cell-directed efferocytosis in the post-partum mammary gland is necessary for tissue homeostasis and future lactation

(2011) Melissa Sandahl et al.   BMC DEVELOPMENTAL BIOLOGY

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma

(2011) Alvarez Hector et al.   CANCER BIOLOGY & THERAPY

Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer

(2011) E. Avilla et al.   CANCER RESEARCH

R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

(2010) S. J. Holland et al.   CANCER RESEARCH

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

(2009) Y Li et al.   ONCOGENE